Physician profile
Glenn Chiang
NPI 1285697227
$1,428.79
in general payments reported to CMS, 2019-2025
19 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $52.95 · 2023: $173 · 2024: $434 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942 · Education: $45.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.84 |
| Education | $45.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $320.77 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Bard Peripheral Vascular, INC. | $159.04 | 2023 | |
| Calliditas Therapeutics US INC. | $111.08 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $104.41 | 2019-2025 | |
| Fresenius USA Marketing, INC. | $90.15 | 2019-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $85.27 | 2024 | Farxiga |
| Novo Nordisk INC | $80.05 | 2024-2025 | Ozempic, Rivfloza |
| Ardelyx, INC. | $72.08 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $71.82 | 2019-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $58.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.99 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $43.54 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $40.00 | 2019-2024 | Jynarque |
| Daiichi Sankyo INC. | $37.24 | 2019-2020 | |
| Averitas Pharma INC. | $30.00 | 2024 | Qutenza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.56 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.42 | 2024 | |
| Akebia Therapeutics INC | $16.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Chiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.